# Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS

> **NCT04987671** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Amylyx Pharmaceuticals Inc.** · enrollment: 14 (estimated)

## Conditions studied

- ALS

## Interventions

- **DRUG:** AMX0035

## Key facts

- **NCT ID:** NCT04987671
- **Lead sponsor:** Amylyx Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-05
- **Primary completion:** 2022-05-11
- **Final completion:** 2023-09
- **Target enrollment:** 14 (ESTIMATED)
- **Last updated:** 2023-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04987671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04987671, "Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04987671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*